Dropped from $8.3+ previous week on weak result Phase 2 study. Results not as bleak as it seem. Solid balance sheet. Waiting for up to $1.3 payment for sold drug. $2.3 cash on hand. Rolontis to be approved (very hugh odds) buy FDA by October 2020. Price targe short term : $5.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.